Ionis Pharmaceuticals IONS Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's non-cash lease expense?
- Ionis Pharmaceuticals (IONS) reported non-cash lease expense of $3.49M in Q1 2026.
- How has Ionis Pharmaceuticals's non-cash lease expense changed year-over-year?
- Ionis Pharmaceuticals's non-cash lease expense increased by 34.7% year-over-year, from $2.59M to $3.49M.
- What is the long-term trend for Ionis Pharmaceuticals's non-cash lease expense?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's non-cash lease expense has grown at a 56.2% compound annual growth rate (CAGR), from $1.72M to $10.25M.
- What does non-cash lease expense mean?
- The non-cash expense recognized for the use of leased property.
- How do you interpret non-cash lease expense?
- Trends in this metric reflect changes in the company's physical footprint and real estate strategy.
- How does non-cash lease expense compare across companies?
- Standard across all industries following the adoption of lease accounting standards.